Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NST-1024 PK Interaction Study with CYP Probe Substrates
NCT05368831Phase 1Completed
- Sponsor
- NorthSea Therapeutics
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of icosabutate in hypertriglyceridemia, sponsored by NorthSea Therapeutics. Primary endpoints: Area under the plasma concentration-time curve from time zero to time t at 15 days and Maximum observed plasma concentration at 15 days. Started Jul 2022; status: completed.
02
Drugs
icosabutate
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT05368831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05368831.